Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.
暂无分享,去创建一个
Xiangao Huang | Yang Zhang | K. Toellner | S. Chen‐Kiang | Yang Zhang | Kai-Michael Toellner | Selina Chen-Kiang | Jamieson Bretz | Josefina Garcia | Lin Kang | Xiangao Huang | Lin Kang | Josefina Garcia | Jamieson Bretz
[1] Andreas Radbruch,et al. Chemotactic Responsiveness Toward Ligands for CXCR3 and CXCR4 Is Regulated on Plasma Blasts During the Time Course of a Memory Immune Response1 , 2002, The Journal of Immunology.
[2] V. Godfrey,et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. , 1998, Genes & development.
[3] A. Strasser,et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.
[4] D. Franklin,et al. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. , 1997, Immunity.
[5] R. Noelle,et al. Short-lived and Long-lived Bone Marrow Plasma Cells Are Derived from a Novel Precursor Population , 2002, The Journal of experimental medicine.
[6] John Calvin Reed,et al. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. , 1997, Immunity.
[7] K. Toellner,et al. Heterogeneity of lymphoid tissue inducer cell populations present in embryonic and adult mouse lymphoid tissues , 2008, Immunology.
[8] F. Finkelman,et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice , 1996, The Journal of experimental medicine.
[9] Jun Zhang,et al. Sites of specific B cell activation in primary and secondary responses to T cell‐dependent and T cell‐independent antigens , 1991, European journal of immunology.
[10] Andreas Radbruch,et al. Lifetime of plasma cells in the bone marrow , 1997, Nature.
[11] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[12] M. Roussel,et al. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.
[13] J. Buerstedde,et al. Loss of Pax5 promotes plasma cell differentiation. , 2006, Immunity.
[14] S. Ely,et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. , 2002, Immunity.
[15] R. Bataille,et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. , 2007, Cancer research.
[16] Qiong Shen,et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination , 2006, Nature Immunology.
[17] G. Morgan,et al. Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.
[18] P. Pandolfi,et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.
[19] L. Staudt,et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.
[20] M. Tourigny,et al. Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response , 2000, The Journal of experimental medicine.
[21] A. Strasser,et al. Loss of the Pro-Apoptotic BH3-only Bcl-2 Family Member Bim Inhibits BCR Stimulation–induced Apoptosis and Deletion of Autoreactive B Cells , 2003, The Journal of experimental medicine.
[22] Andreas Villunger,et al. p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.
[23] G. Kelsoe,et al. In situ studies of the primary immune response to (4-hydroxy-3- nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations , 1991, The Journal of experimental medicine.
[24] T. Mak,et al. Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.
[25] Brian J. Smith,et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.
[26] D. R. Taylor,et al. Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation , 1996, The Journal of experimental medicine.
[27] T. Taniguchi,et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.
[28] J. Nevins,et al. Regulation of the cyclin E gene by transcription factor E2F1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] M. Hendrix,et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.
[30] E. Campo,et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.
[31] Neal N. Iwakoshi,et al. Plasma cell differentiation requires the transcription factor XBP-1 , 2001, Nature.
[32] David L. Jaye,et al. MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation , 2004, Cell.
[33] K. Calame,et al. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.
[34] Kuo-I Lin,et al. Blimp-1-Dependent Repression of Pax-5 Is Required for Differentiation of B Cells to Immunoglobulin M-Secreting Plasma Cells , 2002, Molecular and Cellular Biology.
[35] D. Tenen,et al. Defective B cell receptor‐mediated responses in mice lacking the Ets protein, Spi‐B , 1997, The EMBO journal.
[36] S. Ely,et al. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[37] C. O'keefe,et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.
[38] Kenneth G. C. Smith,et al. The phenotype and fate of the antibody‐forming cells of the splenic foci , 1996, European journal of immunology.
[39] L. Staudt,et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.
[40] Erinna F. Lee,et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains , 2007, Proceedings of the National Academy of Sciences.
[41] R. Hardy,et al. Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. , 1996, Immunity.
[42] J. Cyster,et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.
[43] K. Basso,et al. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells , 2005, Nature Immunology.
[44] Juan F. García,et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.
[45] Roger Sciammas,et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. , 2006, Immunity.
[46] D. Green,et al. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.